IO Biotech's Combo Therapy For Skin Cancer Falls Just Short, Eyes FDA Talks Later This Year

Why is Amazon expanding same-day grocery delivery? How will Air Canada flight cancellations affect travel? What are the impacts of Trump's chip deal with Nvidia? Why is the BLS jobs data report under scrutiny? How is Walmart's new grocery discount aiding employees? What led to the surge in crypto exchange Bullish’s IPO? Why is GE Appliances shifting production to the US?

IO Biotech's Combo Therapy For Skin Cancer Falls Just Short, Eyes FDA Talks Later This Year

benzinga.com/news/health-care/25/08/47032184/io-biotechs-combo-therapy-for-skin-cancer-falls-just-short-eyes-fda-talks-later-this-year

IO Biotech (NASDAQ:IOBT) on Monday released topline results from the pivotal Phase 3 trial of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio (imsapepimut and etimupepimut, adjuvanted).
The trial evaluated Cylembio in combination with Merck & Co…

This story appeared on benzinga.com, 2025-08-11 14:09:05.